AlphaTON Capital has $24.5M in Assets and 23.4M Shares Outstanding, No Debt, No Convertibles, with $11M in Cash, Deposit of $4M Provided for 576 B300 AI GPUsMiami, FL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) ("AlphaTON" or the "Company"), the world's leading public technology company scaling the Telegram super-app with an addressable market of one billion monthly active users, today announced its participation at the WSB Redacted Live Event at the Miami Convention Center. lph ...

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.NASDAQ : IBRXImmunityBioToday's Change( 6.79 %) $ 0.44Current Price$ 6.92Key Data PointsMarket Cap$6.4BDay's Range$ 5.71 - $ 7.1052wk Range$ 1.83 - $ 7.98Volume96MAvg Vol19MGross Margin80.41 %ImmunityBio (IBRX +6.79%), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what ...

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years. ...

Core Insights - BullFrog AI Holdings, Inc. is hosting a webinar on October 30, 2025, to discuss its advancements in drug development using AI and machine learning [1] - The event will feature insights from the founder and CEO, Vin Singh, highlighting the company's innovative AI-driven platforms and recent product launches [2] Company Overview - BullFrog AI focuses on transforming drug discovery and development through its scalable AI-driven platforms, including the BullFrog Data Networks™ Solutions Library and the bfLEAP™ causal AI engine [2] - The newly launched bfPREP™ module automates data cleansing and standardization, providing a flexible toolkit for drug development [2] - The company has strategic global collaborations, notably with CRO Sygnature Discovery, aimed at expanding commercial reach and driving revenue growth [2] Event Details - The webinar will include a live Q&A session following the presentation, allowing attendees to engage directly with the company's leadership [3] - Registration for the free webinar is available online, with options for pre-submitting questions [4]

Core Insights - Charles River Laboratories International, Inc. (CRL) is set to report its third-quarter 2025 results on November 5, with adjusted earnings per share (EPS) of $3.12 in the last quarter exceeding the Zacks Consensus Estimate by 24.80% [1] Q3 Estimates - The Zacks Consensus Estimate for CRL's revenues is $984.6 million, indicating a 2.5% decline from the previous year [2] - The Zacks Consensus Estimate for EPS is $2.32, reflecting a 10.4% year-over-year decrease [2] Estimate Revision Trend - Earnings estimates for CRL's third quarter have decreased by 1 cent in the past week [3] Factors Impacting Performance - **Research Models and Services (RMS)**: Expected revenue growth of 6.5% in Q3 2025, driven by strong sales in research model services and favorable pricing, particularly in the GEMS and Insourcing Solutions businesses [4][5] - **Discovery and Safety Assessment (DSA)**: Anticipated revenue decline of 7% due to budget pressures from biopharmaceutical clients and cash constraints faced by smaller biotech firms [6][8] - **Manufacturing Solutions**: Projected revenue drop of 0.6% in Q3 2025, influenced by geopolitical tensions and supply chain disruptions, although the Microbial Solutions business is expected to perform well [9][10] Earnings Whispers - CRL has an Earnings ESP of +0.61% and a Zacks Rank of 3, indicating a moderate chance of beating estimates [11]

Core Insights - AlphaTON Capital Corp. has appointed Wes Levitt as Chief Financial Officer, effective immediately, to support its growth in the TON ecosystem and digital asset markets [1][2]. Company Overview - AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem [5][6]. - The company implements a comprehensive treasury strategy that includes direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders [5]. Leadership and Strategy - Wes Levitt brings extensive experience in finance, investment management, and blockchain strategy, having previously served as Co-CIO at Alpha Sigma Capital Advisors and Head of Strategy at Theta Labs [2][3]. - In his new role, Levitt will oversee finance, accounting, and capital markets operations, while also supporting strategic initiatives to enhance AlphaTON's position within the TON ecosystem [4]. Business Activities - AlphaTON's activities include network validation, staking operations, and the development of Telegram-based applications, as well as potential investments in TON-based decentralized finance protocols and gaming platforms [6]. - The company is also involved in advancing therapies targeting checkpoint resistance pathways, contributing to drug development and strategic counsel for immunotherapy assets [7].

Upgrades - Scotiabank upgraded OpenText (OTEX) to Outperform from Sector Perform with a price target of $50, up from $35, citing increased conviction in the company's content management business [2] - Jefferies upgraded Quanta Services (PWR) to Buy from Hold with a price target of $469, up from $398, noting that the stock's current valuation provides an attractive entry point [2] - UBS upgraded General Motors (GM) to Buy from Neutral with a price target of $81, up from $56, with 2026 and 2027 earnings estimates 35% and 42% above consensus, respectively [3] - Morgan Stanley upgraded ServiceNow (NOW) to Overweight from Equal Weight with a price target of $1,250, up from $1,040, believing the company is well positioned to deliver generative AI capabilities [4] - Wells Fargo upgraded Amazon.com (AMZN) to Overweight from Equal Weight with a price target of $280, up from $245, increasing conviction that Amazon Web Services will see revenue acceleration [5] Downgrades - Morgan Stanley downgraded Adobe (ADBE) to Equal Weight from Overweight with a price target of $450, down from $520, due to concerns over decelerating Digital Media annual recurring revenue [6] - Barclays downgraded Keurig Dr Pepper (KDP) to Equal Weight from Overweight with a price target of $26, down from $39, citing elevated noise and uncertainty from asset reshuffling [6] - Jefferies downgraded Bloom Energy (BE) to Underperform from Hold with a price target of $31, up from $24, due to limited visibility into growth post 2026 [6] - Susquehanna downgraded Knight-Swift (KNX) to Neutral from Positive with a price target of $43, down from $52, cutting estimates across the sector [6] - BofA downgraded Arvinas (ARVN) to Neutral from Buy with a price target of $10, down from $16, following the announcement of a partnership search for a metastatic breast cancer drug [6]

Core Insights - BullFrog AI Holdings, Inc. is leveraging AI and machine learning to enhance drug development processes, focusing on reliable automation with human oversight [1][4] Webinar Details - A live webinar titled "Clinical Data Analysis with Agents: Reliable Automation with Human Oversight" will be presented by Dr. Juan Felipe Beltrán Lacouture on October 6, 2025, at 11:00 am EDT [1][7] - The webinar aims to showcase how BullFrog AI's platforms, bfPREP™ and bfLEAP™, can transform unstructured clinical data into structured datasets for advanced analysis [2][6] Technology and Methodology - BullFrog AI has successfully converted over 10,000 pages of unstructured clinical PDFs into an OMOP-structured dataset, facilitating machine learning applications [2] - The company emphasizes a balance between automation speed and the necessary human oversight to ensure data integrity and reliability [3][4] - The approach focuses on verified automation rather than full automation, aiming to enhance clinical research workflows while maintaining quality control [3] Commitment to Data Integrity - The CEO of BullFrog AI, Vin Singh, highlighted the company's commitment to advancing data integrity and reliability in drug development, showcasing the practical applications of their technologies [4]

Core Insights - Charles River Laboratories International, Inc. (CRL) is positioned for growth due to favorable prospects in its Discovery and Safety Assessment (DSA) segment, supported by strategic acquisitions and collaborations [1][4][9] - The company has experienced a 15.4% decline in stock value over the past year, compared to a 16.6% drop in the industry, while the S&P 500 has risen by 17.4% [2] - CRL has a market capitalization of $7.94 billion and an earnings yield of 6.3%, outperforming the industry's 3.9% yield [2] Growth Drivers - The DSA segment is a key growth driver, with increasing demand for outsourced drug discovery and safety testing services from large pharmaceutical companies and emerging biotechs [4][9] - Recent acquisitions, including Noveprim and SAMDI Tech, have enhanced CRL's capabilities in non-human primate supply and high-throughput screening solutions [5] - Strategic collaborations, such as those with CHDI Foundation and Deciphex, are aimed at advancing treatments and developing AI tools for toxicologic pathology [6][10] Financial Health - As of the second quarter of 2025, CRL reported cash and cash equivalents of $182.8 million, with no short-term debt, indicating a strong solvency position [11] - Long-term debt decreased by 7.1% to $2.33 billion, with a debt-to-capital ratio of 44% [11] Challenges - The company faces a cautious spending environment among biopharmaceutical clients, which may impact service demand and utilization capacity [12] - Foreign exchange fluctuations pose a significant risk, as a considerable portion of CRL's revenue is generated outside the U.S., and the strengthening U.S. dollar has intensified these challenges [13]

Financial Data and Key Metrics Changes - The biosimulation market has historically grown at a 15% CAGR but has fallen below that over the last couple of years, with the company achieving 10% organic growth during this period [15][18] - The company's revenue guidance was adjusted due to project cancellations and delays, impacting the expected growth trajectory [16][18] Business Line Data and Key Metrics Changes - The business is composed of approximately 60% software licensing and 40% consulting services, with the software side remaining relatively unaffected by recent market challenges [17][20] - Renewal rates for software licenses remain consistent at over 90%, with fluctuations primarily due to client bankruptcies and consolidations [20][21] Market Data and Key Metrics Changes - The drug development industry is facing cost constraints and reduced funding, leading to tighter budgets among clients [14][15] - The FDA's recent announcements regarding the reduction of animal testing requirements are seen as a potential tailwind for the biosimulation market, which could enhance growth opportunities [23][24] Company Strategy and Development Direction - The acquisition of Proficiency has expanded the company's total addressable market (TAM) from $4 billion to $8 billion, allowing for increased opportunities in clinical operations [5][6] - The company is focusing on integrating various modeling and simulation techniques to enhance product offerings and cross-selling opportunities [29][30] Management's Comments on Operating Environment and Future Outlook - Management noted that the drug development industry does not respond well to surprises, which has led to a slowdown in project approvals and contract negotiations [16][18] - The company anticipates a return to a more steady flow of project requests in fiscal year 2026, with expectations of regaining a growth rate closer to 15% [18][19] Other Important Information - The company is launching a cloud-based platform, Astra Plus, which is expected to enhance functionality and accessibility for clients [33][34] - The integration of AI technology into the company's products is a key focus for future development [31][34] Q&A Session Summary Question: What are the expectations for renewal rates and future fiscal year performance? - Renewal rates are expected to remain stable at over 90%, with the service side impacted by client cancellations but the software side performing well [20][21] Question: How is the FDA's movement away from animal models affecting the company? - The FDA's announcements regarding biosimulation and animal testing are seen as positive developments that could lead to increased adoption of the company's tools [23][24] Question: What is the company's growth formula regarding new and existing clients? - Software revenue typically comes from 80% renewals, 10% upsells, and 10% new clients, with a focus on cross-selling opportunities [29][30]